Bright Minds Biosciences, Inc. (DRUG), a company dedicated to addressing drug-resistant epilepsy, depression, and various central nervous system disorders, announced on Tuesday the appointment of Stephen D. Collins as Chief Medical Officer, effective immediately. Additionally, the company disclosed that Mark A. Smith will step down from his position as Acting CMO but will remain engaged in an advisory role. Before joining Bright Minds, Collins held the positions of CEO at both Biscayne Neurotherapeutics and Biscayne Pharmaceuticals, the latter of which was acquired by Supernus Pharmaceuticals in 2018.
The material has been provided by InstaForex Company - www.instaforex.com
The material has been provided by InstaForex Company - www.instaforex.com